Author:
Lairson David R.,Parikh Rohan C.,Cormier Janice N.,Chan Wenyaw,Du Xianglin L.
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference62 articles.
1. Cost effectiveness, chemotherapy, and the clinician;Griggs;Breast Cancer Res Treat,2009
2. Measuring economic outcomes of cancer;Fryback;J Natl Cancer Inst Monogr,2004
3. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC);Lee;Breast Cancer Res Treat,2009
4. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects;Au;Breast Cancer Res Treat,2009
5. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses;Campbell;Eur J Cancer,2011
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献